Table 2 Specific characteristics of BM patients (n = 12)

Number of extracerebral metastatic sites at occurrence of BM

   - 1

7

58.3

   - 2

2

16.7

   - ≥ 3

Location of extracerebral metastases

Lung

8

66.7

Liver

2

16.7

Bone

2

16.7

LN

3

25

other

5

41.7

Time from primary tumor to occurrence of BM

< 2 years

9

75

> 2 years

3

25

Number of brain lesions

1

6

50

2

4

33.3

> 2

2

16.7

Location of BM metastases

   - frontal

4

33.3

   - parietal

2

16.7

   - cerebellar

4

33.3

   - temporal

1

8.3

   - dissiminated

1

8.3

Lesion size

1cm

1

8.3

1-2cm

2

16.7

> 2cm

9

75

CNS symptoms

Yes

10

83.3

No

2

16.7

   - psychiatric

1

8.3

   - vertigo

2

16.7

   - headache

5

41.7

   - ataxia

3

25

   - hemiplegia

1

8.3

Local treatment for BM

   - surgery

2

16.7

   - surgery+ SR

1

8.3

   - surgery+WBRT

2

16.7

   - SR

2

16.7

   - SR+WBRT

2

16.7

   - WBRT

3

25

First targeted agent after local control of BM

   - Bevacizumab

2

16.7

   - Sunitinib

7

58.3

   - Sorafenib

2

16.7

   - Temsirolimus

1

8.3